Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Lineage Cell Therapeutics Inc
(NY:
LCTX
)
0.8839
+0.0071 (+0.81%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lineage Cell Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
The Three Best Anti-Aging Stocks to Buy in September
September 19, 2022
These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments
Via
InvestorPlace
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
September 07, 2022
According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78...
Via
Benzinga
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
August 15, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Recap: Lineage Cell Therapeutics Q2 Earnings
August 11, 2022
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For March 10, 2022
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
August 04, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
July 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Upgrades
Via
Benzinga
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
June 02, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics: Q1 Earnings Insights
May 12, 2022
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Preview: Lineage Cell Therapeutics
May 11, 2022
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
May 05, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
May 03, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
April 26, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
April 25, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
April 13, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022
April 11, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Insiders Buying These 4 Penny Stocks
March 30, 2022
The Nasdaq Composite gained around 60 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Insiders Buy Over $1.3M Of 4 Penny Stocks
March 28, 2022
The Dow Jones tumbled more than 150 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
March 24, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
March 21, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics's Return On Capital Employed Insights
March 14, 2022
Benzinga Pro data, Lineage Cell Therapeutics (AMEX:LCTX) reported Q4 sales of $1.20 million. Earnings fell to a loss of $29.19 million, resulting in a 272.61% decrease from last...
Via
Benzinga
Lineage Cell Therapeutics: Q4 Earnings Insights
March 10, 2022
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Lineage Cell Therapeutics's Earnings: A Preview
March 09, 2022
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....
Via
Benzinga
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
March 14, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.